Drug intelligence / Profile preview

MMX

Development stage: Preclinical
Lead developer: Nuovo Biologics
Modality: Peptides
Administration: Oral

Overview

MMX is an anti-cancer peptide drug developed by Nuovo Biologics LLC. It is currently undergoing clinical trials at Auburn University's Research Initiative in Cancer (AURIC) to evaluate its efficacy in treating canine malignant melanoma. The development is supported by a grant from the National Institutes of Health, funded by the U.S. Food and Drug Administration, and aims for eventual FDA approval. The project utilizes a "one-health/one-medicine" approach, leveraging veterinary models to inform human oncology research.

Beyond the preview

Go deeper on MMX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MMX.

Explore the full profile